Health Economics

Articles

• 2018. Guirant L et al. – Health-related quality of life during the first year after a hip fracture: Results of the Mexican arm of the International Cost and Utility Related to Osteoporotic Fractures Study (MexICUROS)
• 2018. Peters ML et al. – Dutch economic value of Radium-223 in metastatic castration-resistant prostate cancer
• 2018. Pialoux G et al. – Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France
• 2017. Prabhu VS et al. – Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States
• 2017. Peters ML et al. – The current total economic burden of diabetes mellitus in the Netherlands
• 2017. Prabhu V et al. – Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK
• 2017. Kobelt G et al. – The burden of multiple sclerosis 2015: Methods of data collection, assessment and analysis of costs, quality of life and symptoms
• 2017. Berger T et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for Austria
• 2017. Dubois B et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for Belgium
• 2017. Havrdova E et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic
• 2017. Rasmussen PV et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for Denmark
• 2017. Lebrun-Frenay C et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for France
• 2017. Flachenecker P et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for Germany
• 2017. Péntek M et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for Hungary
• 2017. Battaglia M et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for Italy
• 2017. Uitdehaag B et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands
• 2017. Selmaj K et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for Poland
• 2017. Sá MJ et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for Portugal
• 2017. Boyko A et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for Russia
• 2017. Oreja-Guevara C et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for Spain
• 2017. Brundin L et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for Sweden
• 2017. Calabrese P et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for Switzerland
• 2017. Thompson A et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for the United Kingdom
• 2017. McArthur et al. – Health care resource utilization and associated costs among metastatic cutaneous melanoma patients treated with Ipilimumab (INTUITION Study)
• 2017. Weijers L et al. – Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada
• 2017. Mennini FS et al. – Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy
• 2017. Kobelt G et al. – New insights into the burden and costs of multiple sclerosis in Europe
• 2017. Soini E et al. – Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland
• 2017. Kauf TL et al. – Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections
• 2017. Young et al. – Cost-utility evaluation of vortioxetine in patients with major depressive disorder experiencing inadequate response to alternative antidepressants in the United Kingdom
• 2017. Cawston et al. – NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK
• 2017. Maiese BA et al. – Hospitalization costs for patients undergoing orthopedic surgery treated with intravenous acetaminophen (IV-APAP) plus other IV analgesics or IV opioid monotherapy for postoperative pain
• 2017. Largeron N et al. – An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany
• 2017. Svedbom A et al. – Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line
• 2017. Stahmeyer JT et al. – Cost-effectiveness of treating hepatitis C with lofosbuvir/ledipasvir in Germany
• 2017. Igarashi A et al. – Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan
• 2017. Igarashi A et al. – Cost-utility analysis of ledipasvir/ sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan
• 2016. Åkerborg Ö et al. – Cost of dementia and its correlation with dependence
• 2016. Zech J et al. – Cost evaluation of gadoxetic acid-enhanced magnetic resonance imaging in the diagnosis of colorectal-cancer metastasis in the liver: Results from the VALUE Trial
• 2016. Choi SE et al. – Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea
• 2016. Bianic F et al. – Cost-effectiveness of everolimus plus reduced tacrolimus in de novo liver-recipients in the Italian setting
• 2016. MacDonald A et al. – The personal burden for caregivers of children with phenylketonuria: A cross-sectional study investigating time burden and costs in the UK
• 2016. Dalén J et al. – Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence
• 2016. Gaultney J et al. – Trial-based cost-effectiveness of abatacept for rheumatoid arthritis patients in Italy
• 2016. Lopez-Belmonte JL et al. – The use of Zostavax in Spain: The economic case for vaccination of individuals aged 50 years and older
• 2016. Svedbom A et al. – Economic burden of psoriasis and potential cost offsets with biologic treatment: A Swedish register analysis
• 2016. Jönsson L et al. – Cost of treatment in patients with metastatic soft tissue sarcoma who respond favourably to chemotherapy. The Sarcoma treatment and Burden of Illness in North America and Europe (SABINE) study
• 2016. Chevalier J et al. – Cost-effectiveness of treatments for relapsing remitting multiple sclerosis: A French societal perspective
• 2016. Chen YJ et al. – Exacerbations, health services utilization, and costs in commercially-insured COPD patients treated with nebulized long-acting β2-agonists
• 2015. Pialoux G et al. – Cost-effectiveness of dolutegravir in HIV-1 treatment-experienced (TE) patients in France
• 2015. Tallman M et al. – Cost-effectiveness analysis of treating acute promyelocytic leukemia patients with arsenic trioxide and retinoic acid in the United States.
• 2015. Svedbom A et al. – Is dibotermin alfa a cost-effective substitute for autologous iliac crest bone graft in single level lumbar interbody spine fusion?
• 2015. Cure S et al. – Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients
• 2015. Kruse et al. – Budgetary impact of treating acute promyelocytic leukemia patients with first line arsenic trioxide and retinoic acid from an Italian payer perspective
• 2015. Cure S et al. – Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy
• 2015. Nilsson J et al. – Burden of herpes zoster and post-herpetic neuralgia in Sweden
• 2015. McGuire A et al. – End of life or end of the road? Are rising cancer costs sustainable? Is it time to consider alternative incentive and funding schemes?
• 2014. Huisman EL et al. – Economic evaluation of pooled solvent/detergent treated plasma versus single donor fresh-frozen plasma in patients receiving plasma transfusions in the United States
• 2014. Huisman EL et al. – Cost-effectiveness and budget impact study of solvent/detergent (SD) treated plasma (octaplasLG®) versus fresh-frozen plasma (FFP) in any patient receiving transfusion in Canada
• 2014. Ariza R et al. – [Cost-minimization analysis of subcutaneous abatacept in the treatment of rheumatoid arthritis in Spain.]
• 2014. Svedbom A et al. – Epidemiology and economic burden of osteoporosis in Switzerland
• 2014. Karabis A et al. – Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: An analysis over 5 years
• 2014. Kim K et al. – Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm
• 2013. Hernlund E et al. – Osteoporosis in the European Union: Medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)
• 2013. Svedbom A et al. – EU Review Panel of IOF. Osteoporosis in the European Union: A compendium of country-specific reports
• 2013. Eijgelshoven I et al. – The time consuming nature of phenylketonuria: A cross-sectional study investigating time burden and costs of phenylketonuria in The Netherlands
• 2013. Das R et al. – Economic evaluation of fulvestrant 500 mg versus generic nonsteroidal aromatase inhibitors in patients with advanced breast cancer in the United Kingdom
• 2013. Borgström F et al. – The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)–quality of life during the first 4 months after fracture
• 2013. Gaultney JG et al. – Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents
• 2013. Svedbom A et al. – Balloon kyphoplasty compared to vertebroplasty and nonsurgical management in patients hospitalised with acute osteoporotic vertebral compression fracture: A UK cost-effectiveness analysis
• 2012. Matlaga BR et al. – Economic outcomes of treatment for ureteral and renal stones: A systematic literature review
• 2012. Annemans L et al. – The impact of treatment with risperidone long-acting injection on the Belgian healthcare system: Results from a budget impact model
• 2011. Yi Y et al. – Economic burden of neural tube defects and impact of prevention with folic acid: A literature review
• 2011. Naik S et al. – Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy
• 2011. Weatherall J et al. – Future characteristics of bypassing agents to improve care of hemophilia inhibitor patients: An economic and health-related quality of life perspective
• 2011. Naik S et al. – Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden
• 2011. Vissers DC et al. – An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer
• 2011. Gaultney JG et al. – Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia
• 2010. Van Eerd MC et al. – Cost-effectiveness study comparing pharmaceutically licensed plasma for transfusion (OctaplasLG®) versus fresh frozen plasma (FFP) in critically Ill patients in the UK
• 2010. de Peuter MA et al. – Cost-effectiveness of catch-up programs in human papillomavirus vaccination
• 2010. Jansen JP et al. – Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands
• 2010. Zlateva G et al. – Burden of anemia in patients with osteoarthritis and rheumatoid arthritis in French secondary care
• 2010. Jansen JP et al. – Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis
• 2010. Verdian L et al. – Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom
• 2009. Parthan et al. – Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck
• 2009. Jansen JP et al. – Cost-effectiveness evaluation of ertapenem versus piperacillin/ tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance
• 2009. Jansen JP et al. – Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK
• 2008. Stam WB et al. – Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands
• 2008. Payne KA et al. – Iron chelation therapy: Clinical effectiveness, economic burden and quality of life in patients with iron overload
• 2008. Hillemanns et al. – Estimation of the incidence of genital warts and the cost of illness in Germany: A cross-sectional study
• 2008. Jansen JP et al – Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands

Posters & Presentations

• 2017. ACR/ARHP Annual Meeting – Cost per Response for Abatacept Versus Adalimumab in Patients with Seropositive, Erosive, Early Rheumatoid Arthritis in the US, Germany, Spain and Canada
• 2017. ISPOR European Meeting – Cost-effectiveness of nivolumab in combination with ipilimumab in first-line treatment of advanced melanoma in three European countries using 28-month overall survival from CheckMate 067
• 2017. ISPOR European Congress – Cost-effectiveness of dabigatran with real world effectiveness evidence
• 2017. ISPOR European Congress – Cost of nivolumab in combination with ipilimumab as first line treatment in advanced melanoma across various European markets
• 2017. ISPOR European Congress – Systematic literature review of economic evaluations and healthcare resource utilisation studies in the treatment of clostridium difficile infection
• 2017. ISPOR European Congress – Potential therapeutic and economic value of risk-stratified treatment as initial treatment of multiple myeloma in Europe
• 2017. AEDV – Congreso Nacional de Dermatologia y Venereologia – Cost-effectiveness of ixekizumab vs. secukinumab in the treatment of moderate to severe plaque psoriasis in Spain
• 2016. ISPOR European Congress – Estimating the Management Cost of HPV-Related Low-Grade and PreCancerous High-Grade Lesions in France
• 2016. ISPOR European Congress – Budget Impact of Apremilast for Active Psoriatic Arthritis in the UK
• 2016. ISPOR European Congress – Cost-Effectiveness Evaluation of Vortioxetine in Major Depressive Episode in the UK Setting
• 2016. ISPOR European Congress – Budget impact of apremilast for moderate to severe plaque psoriasis in the UK
• 2016. ISPOR European Congress – Cost-effectiveness of apremilast in moderate to severe psoriasis in Canada
• 2016. ISPOR European Congress – The Cost of Multiple Sclerosis in 16 European Countries: Functional Status, Symptoms and Mental Factors Drive Costs
• 2016. ISPOR European Congress – Cost-effectiveness analysis of ixekizumab vs. secukinumab in sequential biologic treatment of psoriasis in the UK
• 2016. EUROGIN – Estimating the Management Cost of Cervical Intraepithelial Neoplasia in the UK
• 2016. EULAR Annual Congress – Cost per Response for Abatacept Compared with Adalimumab in the Treatment of Patients with Rheumatoid Arthritis Based on Anti-Citrullinated Protein Antibody Titres in Italy, Spain and Canada
• 2016. ASCO Annual Meeting – Cost per Median Overall Month of Survival in Multiple Myeloma Patients with ≥3 Lines of Therapy or Were Double Refractory
• 2016. ISPOR Annual International Meeting – Anti-CCP2 Quartile Comparison of the Cost per Response for Abatacept Compared to Adalimumab Based on Sample in the US
• 2015. ISPOR European Congress – Are Antimicrobials Paving the Way for All Pharmaceuticals?
• 2015. ISPOR European Congress – Using an Economic Model to Choose Initial Appropriate Antibiotic Therapy Based on Differences in In-Vitro Susceptibility to Ceftolozane/ Tazobactam and Piperacillin/Tazobactam
• 2015. ISPOR European Congress – Cost-Effectiveness of Apremilast in Psoriatic Arthritis in Scotland
• 2015. ISPOR European Congress – Cost-Effectiveness of Abatacept Compared to Adalimumab in Italy Based on a Head-to-Head Outcomes Study in Rheumatoid Arthritis
• 2015. ISPOR European Congress – Cost-Effectiveness of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir for Patients with Chronic HCV in the Netherlands
• 2015. ISPOR European Congress – Cost per Patient with Sustained Viral Response for Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavarin in Genotype 1 Patients With Chronic HCV in the Netherlands
• 2015. ISPOR European Congress – Reduction in Costs over Two Years when Treating with Darunavir/Ritonavir Compared to Atazanavir/Ritonavir in the UK
• 2015. ISPOR European Congress – Cost-Effectiveness of Cetuximab in First-Line Treatment of Patients with Metastatic Colorectal Cancer in Belgium and the Netherlands
• 2015. ISPOR European Congress – Fixed Combination Netupitant and Palonosetron Is a Cost-Effective Intervention for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the UK
• 2015. ISPOR European Congress – Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with Irinotecan Based Chemotherapy for First-Line Treatment of Metastatic Colorectal Cancer. Stratifed Medicine at Work?
• 2015. ISPOR European Congress – Results of a Dutch Cost-Effectiveness Model of Radium-223 in Comparison to Cabazitaxel, Abiraterone, and Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer Previously Treated with Docetaxel
• 2015. ISPOR European Congress – Estimating the Cost-Effectiveness Profile of a Vaccination Programme with a Nine-Valent HPV Vaccine in Italy
• 2015. ISPOR Annual European Congress – Cost-Effectiveness of Apremilast in Moderate to Severe Psoriasis in Scotland
• 2015. ISPOR European Congress – Cost-Effectiveness Analysis of Intravitreal Aflibercept in Diabetic Macular Oedema in Sweden
• 2015. ISPOR Annual International Meeting – Cost-Effectiveness Analysis of Arsenic Trioxide for the Treatment of In-Patients with Acute Promyelocytic Leukemia
• 2014. ISPOR European Congress – Cost Effectiveness of Cetuximab in First-Line Treatment of RAS Wild-Type Metastatic Cancer in Scotland: A Summary of the Submission to the Scottish Medicines Consortium
• 2014. ISPOR European Congress – Literature Review of Decision-Analytical Models Used in the Economic Evaluation of Empirical/Targeted Antifungal Treatments for Invasive Fungal Infections
• 2014. ISPOR European Congress – Cost per Patient in Non Interventional Studies and Added Value of Direct to Patient Contact Service
• 2014. ISPOR European Congress – Systematic Literature Review Assessing Data on the Burden of Allergic Rhinitis from a Cost and Quality of Life Perspective
• 2013. ISPOR Annual European Congress – The Cost Implications of Renal Denervation Therapy at the Hospital Level in the UK
• 2013. ISPOR European Congress – Differences in Healthcare Resource Utilization and Expenditures Among Schizophrenic Patients in the United States by Health Insurance Status, 2007-2008
• 2013. ISPOR European Congress – The Transparency of National Healthcare Costs in the European Union Five (EU-5)
• 2013. ISPOR Europan Congress – Impact of Pharmacoeconomics Modelling on Reimbursement of Medicines in Serbia
• 2013. ISPOR European Congress – Cost-Minimization Analysis of Subcutaneous Abatacept in the Treatment of Rheumatoid Arthritis in Spain
• 2013. ISPOR European Congress – Economic Evaluation of Ceftobiprole Compared to a Combination of Linezolid with Ceftazidime in the Management of Hospitalised Pneumonia in Scotland
• 2013. ISPOR Annual International Meeting – Economic Evaluation of Aclidinium Bromide in the Management of Moderate-to-Severe COPD
• 2012. ISPOR European Congress – Cost-Effectiveness Analysis of Immunonutrition for Upper Gastrointestinal Cancer Patients Undergoing Surgery in British Hospitals
• 2012. ISPOR European Congress – Pharmacoeconomic Evaluation of the Introduction of Universal Varicella Vaccination in Italy
• 2012. European Hematology Association Congress – Cost Effectiveness of Chemotherapy Regimens In Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review
• 2012. ISPOR Annual International Meeting – The Cost- Effectiveness of Telaprevir (TVR) in Combination with Pegylated Interferon-Alfa and Ribavirin (PR) for the Treatment of Genotype 1 (G1) Chronic Hepatitis C Patients: A Post-Hoc Analysis of IL-28B Subgroup
• 2012. ISPOR Annual International Meeting – The Cost-Effectiveness of Telaprevir (TVR) in Combination with Pegylated Interferon-Alfa and Ribavirin (PR) for the Treatment of Geneotype 1 (G1) Chronic Hepatitis C Patients.
• 2011. ISPOR European Congress – Guidelines for Pharmacoeconomic Evaluation for Serbia
• 2011. ISPOR European Congress – Medico-Economic Analysis of the Impact of Malnutrition on the Post-Operative Course of Colorectal Cancer Patients
• 2011. ISPOR Latin America Conference – Replacing MMR by MMRV in Mexico: Assessment of Cost-Effectiveness Based on a Dynamic Transmission Model
• 2011. ISPOR Annual International Meeting – Cost-Effectiveness of Abatacept in Comparison with Other Biologic Therapies for the Treatment of Moderate to Severe Active Rheumatoid Arthritis Patients Who Have Failed to Methotrexate Based Treatment at Essalud in 2010
• 2011. ISPOR Annual International Meeting – Hemophilia A: Patient Impact and Economic Burden of the Disease
• 2010. ISPOR European Congress – The Cost-Effectiveness of Abatacept in Combination with Methotrexate for the Treatment of Patient with Active Rheumatoid Arthritis after an Inadequate Response to Methotrexate in the United Kingdom
• 2010. ISPOR Asia-Pacific Conference – Measurement Strategies for Productivity Loss in Economic Evaluations
• 2009. ISPOR European Congress – Cost-Effectiveness of Mass Varicella Vaccination in France: Economic Consequences of an Intensive Vaccination Program
• 2009. ISPOR European Congress – Critical Review of Economic Models in Type 2 Diabetes
• 2009. ISPOR European Congress – Cost-Effectiveness of Short-Acting Opioids for Breakthrough Pain in Cancer Patients – A Scottish-Based Decision-Analysis Model
• 2009. ISPOR Annual International Meeting – Does Medicare Have an Implicit Cost-Effectiveness Threshold?
• 2008. ISPOR European Congress – A Systematic Review on the Epidemiology and Socioeconomic Burden of Bipolar Disorder in Europe
• 2008. ISPOR European Congress – Modeling of Infectious Diseases and their Treatment for Health Economic Analysis
• 2008. ISPOR European Congress – Budget Impact of the Use of OROS® Hydromorphone Once Daily in Severe Chronic Pain Patients in the German Health Care System
• 2008. ISPOR European Congress – Cost-Effectiveness of Mass Vaccination for Varicella in France with MMRV Versus MMR
• 2008. ISPOR Annual International Meeting – Bayesian Cost-Effectiveness Analysis of Treatment of Ankylosing Spondylitis
• 2006. ISPOR European Congress – Cost-Effectiveness of Fulvestrant as an Additional Endocrine Step in the Treatment Sequence for Hormone Responsive Advanced Breast Cancer
• 2005. ISPOR European Congress – Podium: Cost-Effectiveness of Voriconazole versus Liposomal Amphotericin B for Invasive Aspergillosis Infection in the UK
• 2005. ISPOR European Congress – Resource Use and Costs Associated with the Management of PAP III, PAP IIID AND PAP IV in the Pre-HPV Vaccine Era in Germany
• 2005. ISPOR European Congress – Workshop 21: Pharmacoeconomics and Market Access in Europe: Case Studies in Scotland and in The Netherlands
• 2005. ISPOR European Congress – Workshop 11: The Added Value of Bayesian Belief Networks for Decision Making
• 2005. ISPOR European Congress – The Impact on Decision-Making of Changing Cost-Effectiveness on Health Technologies Over Time
• 1999. ISPOR Annual International Meeting – Pharmacoeconomic Information in Formulary Decision-Making in the United States